Browse by author
Lookup NU author(s): Emeritus Professor Alan Craft
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The safety and efficacy of the new 5HT-3 antagonist granisetron as an antiemetic in children with cancer was evaluated in 40 children at a single doses of 40 mug/kg. No adverse affects attributable to the granisetron were noted. The overall major and complete response rate was 82.5% and this was highest in the younger children. Only 2 patients showed no response. Pharmacokinetic studies showed associations between some pharmacokinetic parameters and age which were no longer apparent after normalisation for body weight. Granisetron is an effective and very well-tolerated antiemetic and appears to be an important addition to the supportive care available for children with cancer. (C) 1995 Wiley-Liss, Inc.
Author(s): Craft, A. W., Price, L., Eden, O. B., Shaw, P., Campbell, R., Pierce, D. M., Murdoch, R., Upward, J.
Publication type: Article
Publication status: Published
Journal: Medical and Pediatric Oncology
Print publication date: 01/07/1995
ISSN (print): 0098-1532
ISSN (electronic): 1545-5017
PubMed id: 7752999
Altmetrics provided by Altmetric